Tonix Pharmaceuticals will participate in the World Vaccine Congress Washington 2025, delivering an oral presentation and leading a panel discussion from April 22-24 in Washington, D.C. The conference provides a critical platform for the biopharmaceutical company to share its latest research and strategic initiatives in vaccine and therapeutic development.
The presentation will offer insights into Tonix's robust pharmaceutical pipeline, which includes several promising candidates across multiple therapeutic areas. Of particular significance is the company's impending New Drug Application submission to the U.S. Food and Drug Administration for TNX-102 SL, a potential treatment for fibromyalgia that has already completed two statistically significant phase 3 studies.
Beyond fibromyalgia treatment, Tonix is advancing multiple innovative research programs. The company recently secured a substantial contract from the U.S. Department of Defense, worth up to $34 million over five years, to develop TNX-4200 – small molecule broad-spectrum antiviral agents designed to enhance medical readiness in biological threat environments.
The conference presentation represents an important opportunity for Tonix to showcase its comprehensive approach to addressing public health challenges, spanning central nervous system disorders, infectious diseases, and immunology. By sharing its scientific advancements, the company aims to demonstrate its commitment to developing transformative therapeutic solutions.
